News Releases

November 19, 2024   Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta

November 7, 2024   NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results

November 5, 2024   NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting

October 4, 2024   NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting

September 16, 2024   NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024

August 1, 2024   NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results

June 20, 2024   NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

May 30, 2024   NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024

May 2, 2024   NextCure Provides Business Update and Reports First Quarter 2024 Financial Results

April 24, 2024   NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024